Clinical studies carried out for or including Sterimar products are relevant in evaluating the effectiveness of the range of nasal spray solutions developed by Sterimar.
They help us learn more objective data about how Sterimar solutions can contribute to optimal nasal hygiene, to the relief of allergy or cold symptoms, and to the prevention of respiratory or ENT infections.
You can find below 3 of the most recent studies, that are still ongoing:
1. Clinical Study – Relief of Nasal Congestion in Babies and Children with Common Cold
Symptom relief for the common cold, with more frequent episodes in babies and children, requires safe and effective solutions to combat nasal congestion, runny nose, or irritation of the nasal mucosa.
Another priority for the health of children is the optimal hygiene of the nasal mucosa and upper respiratory tract, an important measure to prevent complications that can be associated with the common cold.
A clinical trial conducted on a number of 220 participants, aged between 3 months and 2 years, tested the efficacy, long-term safety, and patient tolerance of Sterimar spray.
The purpose of the study is to evaluate the general health and condition of patients using Sterimar spray to combat cold symptoms, compared to the control group who will receive standard treatment.
The following criteria are also evaluated: the need for medication for the condition of the observed patient (the number of paracetamol doses required), the irritation of the nasal mucosa, the rest and sleep quality or disturbance, and the intensity of the symptoms.
You can find more information about the clinical trial for Sterimar Nasal Congestion (Baby) here.
2. A clinical study carried out with the help of 59 volunteers demonstrates the effectiveness of the Sterimar spray for combating the symptoms of allergic rhinitis
The conclusions of this study are based on an evaluation methodology that includes the observation of patients before and after the application of the seawater spray Sterimar.
The nasal and ocular mucous membranes are monitored at intervals of 1 minute, 10 minutes, and one hour after application, to observe the relief of symptoms such as rhinorrhea, nasal congestion, irritation of the nasal tissues, and frequent sneezing.
The study evaluates the general condition of the volunteers and the impact on the sleep schedule or the need to use medication to combat the symptoms caused by allergic rhinitis.
You can read more information about the clinical trial here:
3. A clinical trial evaluated the effects of two Sterimar products – Sterimar BLOCKED NOSE Baby and Sterimar Stop & Protect Cold Baby – for a group of 300 children between the ages of 3 and 4 months years
Changes in common cold symptoms are observed in both of the groups testing the effectiveness of the Sterimar seawater spray and the control group, which will only receive the standard cold treatment.
The study’s findings are relevant in determining the effectiveness of Sterimar devices for relieving cold symptoms in children, but also to determine how quickly the relief of symptoms can occur.
Another criterion evaluated is the usefulness of Sterimar spray in preventing respiratory infections caused by worsening symptoms.
More details about this ongoing clinical trial can be found here.
As these clinical trials are still under assessment and final conclusions have not been reached, we kindly invite you to read more about the studies, by following the links provided above.
An updated article about the conclusion of each trial will be available on our website, after the completion of the clinical studies.